We are international
Donate
• treatment options TEXT SIZE   
imwg guidelines    back

IMWG consensus statement on the role of vertebral augmentation in multiple myeloma
04.06.10

International Myeloma Working Group (IMWG) consensus statement on the role of vertebral augmentation in multiple myeloma1


Following are the recommendations of the IMWG on role of minimally invasive percutaneous injection of polymethyl methacrylate (PMMA), first developed as “vertebroplasty” in France in the late 1980s, as treatment for painful vertebral compression fractures (VCFs).

Consequences of VCF-related kyphosis

  • Compression of abdominal contents
    • Anorexia, weight loss
    • Decreased lung capacity
  • Limited exercise tolerance/physical activity
  • Anterior loading of spine
    • Subsequent fractures
    • Increasing kyphosis and deformity

Types of vertebral augmentation

  • Vertebroplasty: fractured bone fragments are stabilized and strengthened by percutaneous injection of PMMA.
  • Kyphoplasty:  inflation of a balloon in the vertebral body prior to PMMA injection can restore vertebral height and reduce kyphotic deformity in addition to stabilizing the fractured vertebral body.

Indications for vertebral augmentation

  • Primary: severe pain present (pain >7/10 on Visual Analogue Scale)
    • Collapse of one or more vertebra (VCF)
    • Bone destruction (osteolytic/osteopenic) with high risk of collapse of one or more vertebra
  • Secondary: severe pain absent (pain </= 7/10 on VAS)
    • Significant loss of height and/or structural integrity or stability

Contraindications to vertebral augmentation

  • Absolute                                                                    
    • Contraindications to general or local anesthesia
    • Pregnancy
    • Bleeding disorder
    • Infection at the site
    • Pain unrelated to vertebral collapse
    • Cord compression
    • Presence of overt instability
    • Severe cardiopulmonary insufficiency
    • Allergy to procedure-related drugs/contrast
  • Relative
    • Lesions above T3
    • Osteoblastic metastases
    • Patient < 40 years of age
    • Technically not feasible (vertebra plana)
    • Fractures with obstructing plasmacytoma
    • Retropulsed bone

Identification of patients suitable for vertebral augmentation

  • Careful assessment to determine source/severity of pain
  • MRI is essential to document the anatomy and assess spinal cord edema/compression.
  • Assessment of myeloma disease status and potential anti-myeloma treatment needs
  • Assessment of other pain therapy options

Number and location of levels to be considered for treatment

  • 3 or 4 vertebrae per intervention is considered reasonable and feasible during a single procedure, if required.
  • Vertebral augmentation for adjacent or suspect vertebrae may be necessary when there is a fracture with kyphosis in the thoracolumbar region.
  • For practical purposes, T3-L5 is the range that can be performed safely by percutaneous route.

Method of vertebral augmentation

  • Risk of complications, particularly PMMA leakage, is greater with vertebroplasty.
  • The likelihood of clinically significant complications is dependent upon the experience of the operator.
  • The choice of balloon kyphoplasty versus vertebroplasty should be left to the discretion of the operator and based upon the goals of the procedure.

Potential complications of vertebral augmentation

  • Extravasation of PMMA cement
    • Local effects
    • Systemic effects including pulmonary
  • Cord compression (spinal cord)
  • Radiculopathy (foramina)
  • Pneumothorax
  • Retroperitoneal hematoma
  • Infection: local/systemic

Use of vertebral augmentation versus radiation therapy, systemic therapy, or medical pain therapy

  • Vertebral augmentation is the procedure of choice to improve quality of life for painful VCFx.
  • Up-front external beam radiation therapy (EBR) should be considered for patients with plasmacytomata, extramedullary masses, and cord compression.
  • EBR can be performed in one session without risks of anesthesia, bleeding, infections, or compromise of vital structures. 
  • Systemic anti-myeloma therapy is an alternative for rapid reduction in myeloma tumor burden.
  • Medical pain therapy can provide helpful relief as necessary.

Physical rehabilitation from vertebral augmentation

  • A physical rehabilitation program is recommended to maximize recovery from augmentation. 
  • Ideally, this should be in the form of water aerobics and thoracolumbar stabilization with an extension directional focus, under the auspices of a physical therapist.

1MA Husssein et al. The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group Consensus Statement. Leukemia (2008), 1-6.


 related videos
 related articles
IMWG Guidelines for ...
IMWG Guidelines for ...
IMWG Guidelines for ...
IMWG Guidelines for ...
International Myelom...
International Myelom...
A Practical Guide to...
ASCO 2010: A phase I...
ASCO 2010: Bone mark...
ASCO 2010: Elotuzuma...
ASCO 2010: Lenalidom...
ASCO 2010: Mechanism...
ASCO 2010: Modified ...
ASCO 2010: Multiple ...
ASCO 2010: Neurotoxi...
ASCO 2010: Phase I s...
ASCO 2010: Phase Ib ...
ASCO 2010: Results o...
ASCO 2010: Stromal e...
ASCO 2010: Total the...
Clinically relevant ...
Confirmation of the ...
Developing a SNP Cla...
Eliminating the comp...
ESAs not the culprit...
Genetic association ...
Genetic Associations...
Genetic Associations...
Genetic polymorphism...
Genetic Variations A...
Genomic variation in...
IMWG Criteria for th...
Inaugural Summit of ...
International Myelom...
Long-Term Follow-Up ...
Long-Term Follow-Up ...
New Approaches to Tr...
Oncology Nurses Take...
Osteonecrosis of the...
RT-PCR Amplicons in ...
Survival and Years o...
Use of Bisphosphonat...

Common Symptoms Of M...
Statement on the pas...
Myeloma Awareness Mo...
Advocacy Update - Se...
Advocacy Update - Se...

ASCO 2010: A phase II study of a modified pegylated liposomal doxorubicin (PLD), bortezomib, and dexamethasone regimen for patients with previously untreated multiple myeloma (MM).
ASCO 2010: Bone marker assessment as a guide to chronic use of aminobisphosphonates in multiple myeloma.
ASCO 2010: Elotuzumab in combination with bortezomib in patients with relapsed/refractory multiple myeloma: A phase I study.
ASCO 2010: Lenalidomide maintenance after transplantation for myeloma.
ASCO 2010: Mechanism of the antimyeloma activity of PU-H71, a novel purine scaffold HSP90 inhibitor.
ASCO 2010: Modified high-dose melphalan and autologous stem cell transplantation (mHDM/SCT) in the treatment of AL amyloidosis (AL) and/or high-risk myeloma (hM): Analysis of a Southwest Oncology Group trial.
ASCO 2010: Multiple myeloma is characterized by widespread epigenomic alterations with prognostic implications.
ASCO 2010: Phase I study of combined vorinostat (V), lenalidomide (L), and dexamethasone (D) in patients (pts) with relapsed or refractory multiple myeloma (MM).
ASCO 2010: Phase Ib study of oral panobinostat (LBH589) plus lenalidomide (LEN) plus dexamethasone (DEX) in patients (Pts) with relapsed (Rel) or Rel and refractory (Ref) multiple myeloma (MM).
ASCO 2010: Results of an ongoing open-label, phase II study of carfilzomib in patients with relapsed and/or refractory multiple myeloma (R/R MM).
ASCO 2010: Stromal elements and engraftment (ENG) in autologous hematopoietic progenitor cell transplant (autoHCT) for myeloma.
ASCO 2010: Total therapy 3 (TT3) for multiple myeloma (MM): Contributions to survival outcomes of dosing of maintenance components dexamethasone (D), thalidomide (T) and bortezomib (V).
What is multiple myeloma?
Dr. Morie Gertz of the Mayo Clinic in Rochester, MN.
IMWG Guidelines for Facilities and Services for the Management of Myeloma Patients
IMWG Guidelines for the Management of Multiple Myeloma Patients Ineligible for Standard High-Dose Chemotherapy with Autologous Stem Cell Transplantation
IMWG Guidelines for the Prevention of Thalidomide- and Lenalidomide-Associated Thrombosis in Myeloma
IMWG Guidelines for the Use of Bisphosphonates in Myeloma
International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma
International Myeloma Working Group Guidelines on Imaging Techniques in the Diagnosis and Monitoring of Multiple Myeloma1
A Practical Guide to Achieving and Maintaining the Best Response to Lenalidomide in Multiple Myeloma: Roundtable Proceedings
ASCO 2010: A phase II study of a modified pegylated liposomal doxorubicin (PLD), bortezomib, and dexamethasone regimen for patients with previously untreated multiple myeloma (MM).
ASCO 2010: Bone marker assessment as a guide to chronic use of aminobisphosphonates in multiple myeloma.
ASCO 2010: Elotuzumab in combination with bortezomib in patients with relapsed/refractory multiple myeloma: A phase I study.
ASCO 2010: Lenalidomide maintenance after transplantation for myeloma.
ASCO 2010: Mechanism of the antimyeloma activity of PU-H71, a novel purine scaffold HSP90 inhibitor.
ASCO 2010: Modified high-dose melphalan and autologous stem cell transplantation (mHDM/SCT) in the treatment of AL amyloidosis (AL) and/or high-risk myeloma (hM): Analysis of a Southwest Oncology Group trial.
ASCO 2010: Multiple myeloma is characterized by widespread epigenomic alterations with prognostic implications.
ASCO 2010: Neurotoxic and peripheral neuropathic effects in preclinical and clinical studies of carfilzomib (CFZ), a novel proteasome inhibitor (PI).
ASCO 2010: Phase I study of combined vorinostat (V), lenalidomide (L), and dexamethasone (D) in patients (pts) with relapsed or refractory multiple myeloma (MM).
ASCO 2010: Phase Ib study of oral panobinostat (LBH589) plus lenalidomide (LEN) plus dexamethasone (DEX) in patients (Pts) with relapsed (Rel) or Rel and refractory (Ref) multiple myeloma (MM).
ASCO 2010: Results of an ongoing open-label, phase II study of carfilzomib in patients with relapsed and/or refractory multiple myeloma (R/R MM).
ASCO 2010: Stromal elements and engraftment (ENG) in autologous hematopoietic progenitor cell transplant (autoHCT) for myeloma.
ASCO 2010: Total therapy 3 (TT3) for multiple myeloma (MM): Contributions to survival outcomes of dosing of maintenance components dexamethasone (D), thalidomide (T) and bortezomib (V).
Clinically relevant end points and new drug approvals for myeloma
Confirmation of the utility of the International Staging System and identification of a unique pattern of disease in Brazilian patients with multiple myeloma
Developing a SNP Classifier for Predicting Peripheral Neuropathy by Bortezomib in Multiple Myeloma Patients
Eliminating the complete response penalty from myeloma response criteria
ESAs not the culprit: More studies required
Genetic association with thalidomide mediated venous thrombotic events in myeloma indentified using targeted genotyping
Genetic Associations with Bortezomib Mediated Neuropathy in Multiple Myeloma
Genetic Associations with Therapy Response in the HOVON-65/GMMG-HD4 Trial in Patients with Multiple Myeloma
Genetic polymorphisms of EPHX1, Gsk3 beta, TNFSF8 and myeloma cell DKK-1 expression linked to bone disease in myeloma
Genetic Variations Associated with Overall and Progression-Free Survival in Multiple Myeloma Patients Treated with Thalidomide Combinations
Genomic variation in myeloma: design, content, and initial application of the Bank On A Cure SNP Panel to detect associations with progression-free survival
IMWG Criteria for the Diagnosis of Myeloma and Guidelines for the Diagnostic Work-Up of Myeloma
Inaugural Summit of the International Myeloma Working Group Lays the Groundwork for a Course Toward a Cure.
International Myeloma Working Group at ASH 2009
Long-Term Follow-Up of Autotransplantation Trials for Multiple Myeloma: Update of Protocols Conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University of Arkansas for Medical Sciences
Long-Term Follow-Up of Autotransplantation Trials for Multiple Myeloma: Update of Protocols Conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University of Arkansas for Medical Sciences
New Approaches to Treatment for Multiple Myeloma: Durable Remission and Quality of Life as Primary Goals
Oncology Nurses Take the Lead in Providing Novel Therapy Guidelines for Multiple Myeloma
Osteonecrosis of the Jaw and Biphosphonates
RT-PCR Amplicons in the Plasma of Multiple Myeloma Patients
Survival and Years of Life Lost in Different Age Cohorts of Patients With Multiple Myeloma
Use of Bisphosphonates in Multiple Myeloma: IMGW Response to Mayo Clinic Consensus Statement
WHAT IS MULTIPLE MYELOMA
Common Symptoms Of Multiple Myeloma
Statement on the passing of Senator Kennedy
Myeloma Awareness Month 2010
Support
Advocacy Update - September 1, 2009
Advocacy Update - September 15, 2009